登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C97H144FN33O19S2 · xC2HF3O2
分子量:
2159.52 (free base basis)
UNSPSC Code:
51111800
NACRES:
NA.21
Assay:
≥95% (HPLC)
Form:
(Powder or Lyophilized powder or film)
Quality level:
Storage condition:
desiccated
Quality Level
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
SMILES string
O=C(NCCCC1NC(C(CCCNC(N)=N)NC(C(CC2=CC=C(C=C2)O)NC(C3N(CCC3)C(C(CCCCN)NC(C(CCCCN)NC(C(CCCNC(N)=O)NC(C(CC4=CC=C(C=C4)O)NC(C(CSSCC(C(NC(CCCNC(N)=N)C(N)=O)=O)NC1=O)NC(C(CC5=CC6=C(C=CC=C6)C=C5)NC(C(CCCNC(N)=N)NC(C(CCCNC(N)=N)NC(C7=CC=C(C=C7)F)=O)=O)=O)=O)=O)=O
Biochem/physiol Actions
Motixafortide (BKT140, BL-8040) is an orally available, highly selective inverse agonist of CXCR4 (CXC Chemokine Receptor 4). Motixafortide is a potent stem cell mobiliser and anticancer agent. BKT140 potently inhibits CXCL12 induced migration/invasion of small-cell lung cancer cells.
Orally available, highly selective inverse agonist of CXCR4
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression
Leukemia, 31(11), 2336-2346 (2017)
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003
Stem Cells, 25(9), 2158-2166 (2007)
Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140
Clinical Cancer Research, 19(13), 3495-3507 (2013)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3846-5MG | 04065270403889 |
| SML3846-25MG | 04065270403872 |
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持